Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
EPS Growth Recovery in ProgressRecovering
Percentile Rank59
Year-over-Year Change
Year-over-year earnings per share growth rate
Latest
10.61%
↓ 86% vs avg
Percentile
P59
Within normal range
Streak
1 qtr
Consecutive growthRecovering
Average
77.39%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 10.61% |
| Q3 2025 | 5.47% |
| Q2 2025 | 59.52% |
| Q1 2025 | -29.01% |
| Q4 2024 | -12.35% |
| Q3 2024 | 129.09% |
| Q2 2024 | -426.76% |
| Q1 2024 | 13.30% |
| Q4 2023 | -6.23% |
| Q3 2023 | 12.96% |
| Q2 2023 | 30.51% |
| Q1 2023 | -14.73% |
| Q4 2022 | -12.12% |
| Q3 2022 | 14.51% |
| Q2 2022 | 6.02% |
| Q1 2022 | -0.99% |
| Q4 2021 | -8.48% |
| Q3 2021 | 1169.23% |
| Q2 2021 | -89.68% |
| Q1 2021 | 8.62% |
| Q4 2020 | -9.38% |
| Q3 2020 | -20.50% |
| Q2 2020 | 38.79% |
| Q1 2020 | 2.65% |
| Q4 2019 | 927.27% |
| Q3 2019 | -78.85% |
| Q2 2019 | -0.95% |
| Q1 2019 | -82.73% |
| Q4 2018 | 1092.16% |
| Q3 2018 | -37.80% |
| Q2 2018 | -1.20% |
| Q1 2018 | 107.50% |
| Q4 2017 | 197.56% |
| Q3 2017 | -685.71% |
| Q2 2017 | -93.07% |
| Q1 2017 | 676.92% |
| Q4 2016 | 176.47% |
| Q3 2016 | 34.62% |
| Q2 2016 | -52.94% |
| Q1 2016 | 45.16% |